Last update 01 Nov 2024

Liraglutide (Chongqing Paijin)

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms-
Target
GLP-1R
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Chongqing Paijin Biotechnology Co Ltd.Chongqing Paijin Biotechnology Co Ltd.Chongqing Chenan Biopharmaceutical Co., Ltd.Chongqing Chenan Biopharmaceutical Co., Ltd.
Active Organization
Chongqing Paijin Biotechnology Co Ltd.Chongqing Paijin Biotechnology Co Ltd.Chongqing Chenan Biopharmaceutical Co., Ltd.Chongqing Chenan Biopharmaceutical Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Liraglutide (Chongqing Paijin)
CTR20210173 / CompletedPhase 3
多中心、随机、开放、平行对照比较利拉鲁肽注射液和诺和力治疗2型糖尿病患者的有效性和安全性
[Translation] A multicenter, randomized, open, parallel controlled comparison of the efficacy and safety of liraglutide injection and Victoza in the treatment of patients with type 2 diabetes
CTR20191362 / Completed
利拉鲁肽注射液在健康受试者中的随机、开放、两周期、 单次给药、双交叉临床比对试验
[Translation] A randomized, open-label, two-period, single-dose, double-crossover clinical comparative study of liraglutide injection in healthy subjects
100 Clinical Results associated with Liraglutide (Chongqing Paijin)
Login to view more data
100 Translational Medicine associated with Liraglutide (Chongqing Paijin)
Login to view more data
100 Patents (Medical) associated with Liraglutide (Chongqing Paijin)
Login to view more data
2
Literatures (Medical) associated with Liraglutide (Chongqing Paijin)
01 Aug 2010Der InternistQ4 · MEDICINE
NN8022-1807-Studie
Q4 · MEDICINE
Nutrición HospitalariaQ4 · MEDICINE
Tratamiento de obesidad con liraglutide en un paciente con Síndrome de Prader-Willi: reporte de caso
Q4 · MEDICINE
100 Deals associated with Liraglutide (Chongqing Paijin)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 3
CN
Chongqing Chenan Biopharmaceutical Co., Ltd.Chongqing Chenan Biopharmaceutical Co., Ltd.
05 Jul 2021
Diabetes Mellitus, Type 2Phase 3
CN
Chongqing Paijin Biotechnology Co Ltd.Chongqing Paijin Biotechnology Co Ltd.
05 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free